Woburn, MA, Oxford, UK, December 7, 2016 – Replimune Ltd announced today that Dr. Robert Coffin, Ph.D., its founder and CEO, has been honored with the 43rd Annual Inventor of the Year Award by the IPO Education Foundation. Dr. Coffin received the award in Washington D.C. .Dr. Coffin’s invention, now Amgen’s IMLYGIC, is the first in the class of oncolytic immunotherapy drugs to receive marketing approval anywhere in the world. IMLYGIC is designed to replicate in cancer cells leading to oncolysis, whereby the release of tumor derived antigens, virally derived GM-CSF, and replicated IMLYGIC produce potent antitumor immune responses. As such, IMLYGIC is potentially broadly applicable to solid tumors even though it is currently only approved in melanoma.
Dr. Coffin is a pioneer in the fields of oncolytic viral therapy and cancer immunotherapy having spent more than15 years conceiving and developing IMLYGIC and related products. This award recognizes the dedication required of Dr Coffin and the many dedicated professionals involved in the entire innovation and drug development process through to the ultimate commercialization of life saving treatments. This year, the Foundation chose to honor the inventors of six drugs in the field of cancer immunotherapy, which in addition to IMLYGIC were BLINCYTO (Amgen), YERVOY (BMS), NIVOLUMAB (BMS), KEYTRUDA (Merck) & TECENTRIQ (Roche).